Altogether, this suggests that the intestinal-specific Pgc1α ablation protects against liver steatosis via modulation of liver X receptor (Lxr)-driven cholesterol and fatty acid metabolism. The gene discussed is PPARGC1A; the disease is fatty liver disease.